Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | FPR3 | P25089 | 1/20 | 0.52 |
| ▸ | FPR2 | P25090 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 6/20 | 0.50 |
| ▸ | BCHE | P06276 | 4/20 | 0.50 |
| ▸ | KAT7 | O95251 | 1/20 | 0.50 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870792 | 0.89 | ACKR3 (0.67) | ACKR3USP30HTR6BCHEKAT7 | |
| SCHEMBL5871116 | 0.89 | ACKR3 (0.67) | ACKR3USP30HTR6BCHEKAT7 | |
| SCHEMBL31227478 | 0.85 | USP30 (0.53) | ACKR3USP30CYP2C9FPR3FPR2 | |
| SCHEMBL5870835 | 0.82 | USP30 (0.51) | ACKR3USP30CYP2C9FPR3FPR2 | |
| SCHEMBL5870833 | 0.82 | USP30 (0.51) | ACKR3USP30CYP2C9FPR3FPR2 | |
| SCHEMBL27406245 | 0.81 | ACKR3 (0.53) | ACKR3USP30CYP2C9HTR6BCHE | |
| SCHEMBL13777209 | 0.81 | ACKR3 (0.53) | ACKR3USP30CYP2C9HTR6BCHE | |
| SCHEMBL6214983 | 0.80 | ACKR3 (0.57) | ACKR3USP30HTR6BCHEKAT7 | |
| SCHEMBL8237687 | 0.80 | ACKR3 (0.57) | ACKR3USP30HTR6BCHEKAT7 | |
| SCHEMBL21605819 | 0.80 | ACKR3 (0.57) | ACKR3FPR3FPR2HTR6BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129228-B2 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | CUNY GREGORY D (US) | 2004-10-21 | — | — | US | disclosed |
| US-6677332-B1 | AMIDE-SUBSTITUTED PIPERIDINE OR AZEPINE DERIVATIVES TO TREAT DRUG ABUSE AND TINNITUS | SEPRACOR, INC. | 2004-01-13 | — | — | US | disclosed |
| US-6645980-B1 | Ligands for biological receptors such as opiate receptors or G-protein coupled receptors used for treating pain, drug dependence or tinnitus in mammals | SEPRACOR INC. | 2003-11-11 | — | — | US | disclosed |
| US-6635661-B2 | Piperidinyl amide compounds | SEPRACOR INC. | 2003-10-21 | — | — | US | disclosed |
| WO-2002069895-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002046157-A2 | METHODS FOR THE STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED PIPERIDINES | SEPRACOR, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| EP-1187810-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001092226-A1 | HETEROCYCLIC ANALGESIC COMPOUNDS AND METHOD OF USE THEREOF | SEPRACOR, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2000071518-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | ACKR3 248/4885USP30 3782/4885CYP2C9 794/4885 |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | ACKR3 248/4885USP30 3782/4885CYP2C9 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.